Medgenics(Regs) Share Discussion Threads

[rpaco] 18/8/2010 16:26

Something very fishy with these shares as opposed to MEDU which are of the same company. Directors all seem to hold MEDG and not MEDU. MEDU has no assets or accounts listed. Both MEDG and MEDU have equal value and yet MEDG are half the share price of MEDU.
Are MEDG being manipulated by some major holders shorting every couple of weeks, while MEDU do not move at the same time.

[sicilian_kan] 03/8/2010 23:40

Medgenics are going to be presenting at the Rodman and Renshaw 2010 Pharma conference in Sept 2010

[sicilian_kan] 19/7/2010 13:05

Excellent news out mid-morning...

Medgenics Announce Encouraging New Results

TIDMMEDG

RNS Number : 5442P
Medgenics Inc
19 July 2010

Medgenics, Inc.
('Medgenics' or the 'Company')

Medgenics Announces Encouraging New Results in Phase I/II Trials to Treat
Anaemia

Higher Dose EPO Biopumps Produce Dose-Dependent Increases in Haemoglobin

Misgav, Israel and London, UK -19 July 2010 - Medgenics, Inc. (AIM: MEDG, MEDU), the company that has developed a novel technology for the manufacture and delivery of therapeutic proteins continuously in patients using their own
tissue, is pleased to announce encouraging new results in the Company's ongoing Phase I/II clinical trials with EPODURE to treat anaemia. As announced on 22 June 2010, two new patients have joined the Company's Phase I/II clinical trial, using Biopumps producing middle dose levels of erythropoietin ('EPO') (40 IU/kg/day). Now, through 4 weeks following treatment, these patients have shown a greater therapeutic response to the higher dose than was obtained in similar patients in the low dose group (20 IU/kg/day). Although individual patient response to EPO dose varies, comparing the response in the corresponding patients treated with half the dose with the response in these two patients receiving the higher dose shows:

� 1.1-1.2 g/dl elevation of haemoglobin, versus to 0.5-0.75g/dl in the
low-dose group; and

� substantially greater rise in new red blood cells (reticulocyte count):
120-200 versus 60 reticulocytes/nl in the comparable patients.

Four weeks post-treatment is a typical period used for evaluating initial haemoglobin response to a given EPO dose. Taken together thus far, these findings indicate that the mid-dose patients are having a stronger response than seen in the low dose group.

These results, although only in two patients for their first month of treatment, are encouraging early signs of a dose-dependent response - an important objective of the current new stage of the trials.

In the first part of the Company's Phase I/II clinical trial, the focus was on the (20 IU/kg/day) dose, equivalent to the lowest recommended dose for EPO, administered in 6 of the patients treated, with one patient treated with the
middle recommended dose (40 IU/kg/day). The Biopumps produced EPO continuously in all the patients, elevating or maintaining the haemoglobin levels in most, even with the lowest EPO dose, with most continuing for the 6 month duration of the trial and one for more than 20 months.

This second part of the trial is aimed at treating new patients with the medium and higher EPODURE doses to confirm that haemoglobin will be safely maintained or elevated over the period of the trial using these higher dosage levels of EPO delivery, and to show evidence of dose-dependence: greater administered EPODURE dose should generally result in greater haemoglobin response.

Biopumps produced from the two new patients who entered this phase of the study were administered to them on 17 June 2010. Only 3-4 Biopumps were needed in each patient to deliver a total of 40 IU/kg/day. As noted, this has now been followed at 4 weeks post-treatment by greater haemoglobin response in these patients than has been seen in the previous patients. These results are a significant step towards demonstrating sustained dose-dependent haemoglobin
response, and in the Company's development of EPODURE Biopump.

Dr. Andrew Pearlman, CEO of Medgenics commented: "We are pleased with the strong response of these first patients treated in the new part of our study. We are particularly gratified by the greater rise in haemoglobin in these patients compared to the lower dose counterparts, a finding that supports our belief that EPODURE is a dosable treatment. We are confident that the coming weeks and months will confirm for the mid-dose what we have shown at lower dose: that a single administration of Biopumps can provide many months of effective anaemia therapy in these patients replacing scores of EPO injections. We now look forward to following these patients, while recruiting additional patients to the trial in the coming months."

[ihavenoclue] 13/7/2010 12:20

I haven't been on in a few weeks so didn't notice the rise, and then drop back to current levels.

I am above evens on it so I will pop back in a few weeks or so :)

[sicilian_kan] 11/7/2010 17:11

From md rod on iii.

Hi regreu

There were a few trades on PLUS markets:



Only small volume but the last 2 were Sells and this was enough for the MM's to mark down the Bid and hence the mid dropped.

As I say the volume is very low so a couple of Buys could as easily result in the reverse.

Tom Bulford (RHPS) issued a few words to his subscribers via email today after close the first part is stating what we already know via the RNS but the later is worth noting with regards to the advice he offers to his subscribers:

'' MEDGENICS (MEDU): Medgenics has issued a statement drawing attention to the gap that has opened up between the price of the MEDG line and that of the unrestricted MEDU line. It says that "all of its issued and outstanding Common Shares, whether trading on the MEDU line or the MEDG line, rank pari passu in all respects and carry equal voting rights and equal rights to dividends".

That does not mean that they will automatically trade at the same price, because that depends upon the supply and demand for each class, and clearly the ease of dealing in the MEDU line has led to them being at a premium. As I have said before, I will continue to report the price of the MEDU, but common sense says that you should buy whichever line is the cheaper. BUY UP TO 13p''

All the best

Regs

[sicilian_kan] 05/7/2010 22:20

8th biggest gainer today at 20%. And hopefully more to come. If it is to catch up with MEDU, it has to go all the way to 17.5p at present, i.e. another 80%.

[sicilian_kan] 05/7/2010 21:40

Agreed. To be honest, I've never understood why people have chosen SAR, AZM etc. instead of Medgenics.

[bikkit] 05/7/2010 20:54

so few PI,s posting, surprising after todays rise !!

[sicilian_kan] 05/7/2010 08:22

Statement re: Share Price Discrepancy

TIDMMEDG

Medgenics Inc
05 July 2010

?
Medgenics, Inc.
('Medgenics' or the 'Company')
Statement Regarding Share Price Discrepancy

Medgenics (AIM: MEDG and MEDU), the company that has developed a novel
technology for the manufacture and delivery of therapeutic proteins continuously in patients using their own tissue, has noted the widening discrepancy between the mid-market price of the MEDU and MEDG quotes for common shares of par value US $0.0001 each in the Company ("Common Shares").

The Company would like to confirm that all of its issued and outstanding Common
Shares, whether trading on the MEDU line or the MEDG line, rank pari passu in
all respects and carry equal voting rights and equal rights to dividends. The
only difference between the two quotes (MEDU and MEDG) is that the Common Shares trading on the MEDG line were when issued and remain subject to restrictions on transfer under the US Securities Act of 1933 (as amended) (the "US Securities Act"). The MEDG line of Common Shares cannot be settled electronically in the CREST system and, instead, settle in CREST only on a cash basis, with the buyer being responsible for re-registering the certificated holding. Buyers and sellers of the MEDG line of stock are both required to complete a representation letter in connection with a dealing in Common Shares trading on the MEDG line in order to assure compliance with the transfer restrictions and for settlement to be facilitated. A significant number of the Common Shares trading on the MEDG line may now qualify to have the restrictions lifted and for migration to the MEDU line of Common Shares.

Other than the transfer restrictions, the Company confirms that there are no
differences in rights between the Common Shares quoted on the MEDU line and
those quoted on the MEDG line.

For further information regarding the applicable restrictions on transfer on
MEDG quoted Common Shares, the ability to transfer Common Shares from the MEDG
line onto the MEDU line, participation in the depository interest arrangements
that have been established by the Company and the transfer of Common Shares
within CREST, shareholders should refer to the announcement made by the Company
on 12 November 2008 or contact the Company directly at
[e-mail].

[sicilian_kan] 05/7/2010 08:21

This share is under half the value of MEDU and there is no reason for this discrepancy. It should be at MEDU's value.

[sicilian_kan] 05/7/2010 08:20

Here goes...should be several more tick ups today...confirmation from the company as to what people should have been checking...! Go MEDG.

[sicilian_kan] 25/6/2010 23:23

This is an interesting read.

[sicilian_kan] 25/6/2010 16:16

MEDU is clearly the better share to trade. MEDG is clearly the better share to buy and hold.

[sicilian_kan] 25/6/2010 16:15

If the trials keep on going well, an offer will come in, I very much hope. Any purchaser will need to put in an offer before licenses are granted for each treatment. Maybe in 6 - 12 months time.

[ihavenoclue] 25/6/2010 16:02

Where as MEDU sails past 25p for the third time. I would LOVE a share offer for all the shares at 30p+

[ihavenoclue] 25/6/2010 15:59

Seems it got a nose bleed at 8.5p and went back down again

[arnie72] 24/6/2010 14:04

Going in the right direction at least!

[giant steps] 24/6/2010 13:25

every point counts

[sicilian_kan] 24/6/2010 13:23

Well, there's another one today.

[sicilian_kan] 23/6/2010 20:15

You are right. But I know long term, I will be right with MEDG rather than MEDU. Hare and tortoise, all that sort of thing.

[ihavenoclue] 23/6/2010 17:11

Well no big rise and 0.12p isn't even a proper tick up IMHO

[sicilian_kan] 23/6/2010 08:37

Well, I'm off to work now, so will be returning later. Hope to see a big rise here in my absence.

[themoneymonster2] 23/6/2010 08:36

Don't get me wrong, I have enough to make a difference if they get to even 15p.

[sicilian_kan] 23/6/2010 08:35

At last, the first tick up! Many more hopefully??